Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 340

1.

Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Ernst NM, Suryapranata H, Miedema K, Slingerland RJ, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Zijlstra F, van 't Hof AW.

J Am Coll Cardiol. 2004 Sep 15;44(6):1187-93.

2.

The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.

Hermanides RS, van Werkum JW, Ottervanger JP, Breet NJ, Gosselink AT, van Houwelingen KG, Dambrink JH, Hamm C, ten Berg JM, van 't Hof AW; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group.

Catheter Cardiovasc Interv. 2012 May 1;79(6):956-64. doi: 10.1002/ccd.23165. Epub 2011 Dec 12.

PMID:
22162050
4.

Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.

J Am Coll Cardiol. 2010 Aug 3;56(6):463-9. doi: 10.1016/j.jacc.2009.08.093.

5.

Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.

Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, Todaro D, Giammarinaro M, Leone AM, Niccoli G, Andreotti F, Mazzari MA, Schiavoni G, Crea F.

J Cardiovasc Med (Hagerstown). 2009 Mar;10(3):245-51. doi: 10.2459/JCM.0b013e32832180d9.

PMID:
19262211
6.

Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).

Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ; TARGET Investigators.

J Am Coll Cardiol. 2003 Oct 1;42(7):1188-95.

7.
9.

Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.

Bilsel T, Akbulut T, Yesilcimen K, Terzi S, Sayar N, Dayi SU, Akgoz H, Ergelen M, Ciloglu F.

Heart Vessels. 2006 Mar;21(2):102-7.

PMID:
16550311
10.

Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.

Desch S, Siegemund A, Scholz U, Adam N, Eitel I, de Waha S, Fürnau G, Lurz P, Wetzel S, Schuler G, Thiele H.

Clin Res Cardiol. 2012 Feb;101(2):117-24. doi: 10.1007/s00392-011-0372-6. Epub 2011 Oct 21.

PMID:
22015616
11.
12.

Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

van 't Hof AW, Valgimigli M.

Drugs. 2009;69(1):85-100. doi: 10.2165/00003495-200969010-00006. Review.

PMID:
19192938
13.

Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.

Konopka A, Spychalska J, Sitkiewicz D, Zdebska E, Pilichowska I, Piotrowski W, Stepińska J.

Am J Cardiovasc Drugs. 2007;7(6):433-9.

PMID:
18076210
14.

Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.

JAMA. 2008 Apr 16;299(15):1788-99. doi: 10.1001/jama.299.15.joc80026. Epub 2008 Mar 30.

PMID:
18375998
16.

Tirofiban use with clopidogrel and aspirin decreases adverse cardiovascular events after percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials.

Sethi A, Bahekar A, Doshi H, Bhuriya R, Bedi U, Singh S, Khosla S.

Can J Cardiol. 2011 Sep-Oct;27(5):548-54. doi: 10.1016/j.cjca.2011.03.017. Epub 2011 Aug 25.

PMID:
21871775
17.

Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.

Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A.

Thromb Res. 2013 Jul;132(1):e36-41. doi: 10.1016/j.thromres.2013.05.029. Epub 2013 Jun 19.

PMID:
23791395
18.
19.
20.

Survival benefit with concomitant clopidogrel and glycoprotein IIb/IIIa inhibitor therapy at ad hoc percutaneous coronary intervention.

Gumina RJ, Yang EH, Sandhu GS, Prasad A, Bresnahan JF, Lennon RJ, Rihal CS, Holmes DR Jr, Singh M.

Mayo Clin Proc. 2008 Sep;83(9):995-1001. doi: 10.4065/83.9.995.

PMID:
18775199

Supplemental Content

Support Center